Skip to main content

Table 12 Current ongoing early phase I/II trials with mTOR/PI3K inhibitors

From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

mTOR/PI3K pathway Inhibitors

Drug name

Mechanism of action

Clinical trial (Phase)

Study design

Disease

Gedatolisib (PF-05212384)

pan-PI3K/mTOR inhibitor

NCT03065062 (1)

Combination with Palbociclib

Advanced tumors including squamous NSCLC

Idelalisib

PI3K inhibitor

NCT03257722 (1)

Combination with Pembrolizumab

Advanced NSCLC with progression on first line therapy

Nab Rapamycin (ABI-009)

mTOR inhibitor

NCT03190174 (1/2)

Combination with Nivolumab

Advanced solid tumors including NSCLC

RMC-5552

bi-steric mTORC1-selective inhibitor

NCT04774952 (1/1b)

Monotherapy

Advanced solid tumors including NSCLC

Sapanisertib

mTORC1/mTORC2 inhibitor

NCT02417701 (2)

Monotherapy

KRAS mutant NSCLC with KEAP1 mutation

Sirolimus

mTOR inhibitor

NCT01737502 (1/2)

Combination with Auranofin

Advanced or Recurrent Lung Cancer